27611-39-8Relevant articles and documents
Configurational Isomers Induced Significant Difference in All-Polymer Solar Cells
Wang, Hengtao,Chen, Hui,Xie, Weicheng,Lai, Hanjian,Zhao, Tingxing,Zhu, Yulin,Chen, Lin,Ke, Chunxian,Zheng, Nan,He, Feng
, (2021)
The design of polymer acceptors plays an essential role in the performance of all-polymer solar cells. Recently, the strategy of polymerized small molecules has achieved great success, but most polymers are synthesized from the mixed monomers, which seriously affects batch-to-batch reproducibility. Here, a method to separate γ-Br-IC or δ-Br-IC in gram scale and apply the strategy of monomer configurational control in which two isomeric polymeric acceptors (PBTIC-γ-2F2T and PBTIC-δ-2F2T) are produced is reported. As a comparison, PBTIC-m-2F2T from the mixed monomers is also synthesized. The γ-position based polymer (PBTIC-γ-2F2T) shows good solubility and achieves the best power conversion efficiency of 14.34% with a high open-circuit voltage of 0.95?V when blended with PM6, which is among the highest values recorded to date, while the δ-position based isomer (PBTIC-δ-2F2T) is insoluble and cannot be processed after parallel polymerization. The mixed-isomers based polymer, PBTIC-m-2F2T, shows better processing capability but has a low efficiency of 3.26%. Further investigation shows that precise control of configuration helps to improve the regularity of the polymer chain and reduce the π–π stacking distance. These results demonstrate that the configurational control affords a promising strategy to achieve high-performance polymer acceptors.
Strategic end-halogenation of π-conjugated small molecules enabling fine morphological control and enhanced performance of organic solar cells
Furukawa, Seiichi,Yasuda, Takuma
, p. 14806 - 14815 (2019)
Organic solar cells based on π-conjugated small molecules (SM-OSCs) have developed rapidly in the past few years. Nevertheless, the design strategies of small-molecule (SM) donors for high-efficiency SM-OSCs require further improvement. Halogenation is an effective way to modulate their electronic properties, and to date, fluorination has been most widely used for the design of organic photovoltaic materials. However, the feasibility and utility of photovoltaic materials incorporating other halogens, especially heavier bromine and iodine, have not been fully explored. Here, a novel family of SM donor materials, having the same π-conjugated backbone but different terminal halogen groups (F, Cl, Br, and I), are systematically designed and developed. Furthermore, the structure-property-function relationships stemming from the variations in the substituted halogen atoms are discussed. Among these end-halogenated SM donors, the I-containing material shows remarkably high photovoltaic performance in the fullerene-based SM-OSCs, demonstrating power conversion efficiencies of up to 9.2% without any processing additives and post-treatment processes. Detailed morphological analyses reveal that end-halogenation with heavier halogen atoms, typified by I and Br, effectively modulated the interfacial free energy of the blend with a fullerene acceptor and facilitate the formation of fine interpenetrating networks in the active layer. This study establishes a new design paradigm featuring end-halogenation for producing high-performance photovoltaic materials for SM-OSCs.
The discovery, design and synthesis of potent agonists of adenylyl cyclase type 2 by virtual screening combining biological evaluation
Li, Shanshan,Song, Gao,Wang, Liang-Liang,Weng, Zhiying,Xu, Guowei,Yang, Weimin,Yang, Yanming,Yang, Yaqing,Zhang, Jiajun,Zuo, Zhili
supporting information, (2020/02/27)
Adenylate cyclases (ACs), play a critical role in the conversion of adenosine triphosphate (ATP) into the second messenger cyclic adenosine monophosphate (cAMP). Studies have indicated that adenylyl cyclase type 2 (AC2) is potential drug target for many diseases, however, up to now, there is no AC2-selective agonist reported. In this research, docking-based virtual screening with the combination of cell-based biological assays have been performed for discovering novel potent and selective AC2 agonists. Virtual screening disclosed a novel hit compound 8 as an AC2 agonist with EC50 value of 8.10 μM on recombinant human hAC2 + HEK293 cells. The SAR (structure activity relationship) based on the derivatives of compound 8 was further explored on recombinant AC2 cells and compound 73 was found to be the most active agonist with the EC50 of 90 nM, which is 160-fold more potent than the reported agonist Forskolin and could selectively activate AC2 to inhibit the expression of Interleukin-6. The discovery of a new class of AC2-selective agonists would provide a novel chemical probe to study the physiological function of AC2.
